SecBot SecBot
15-12G ·Filed Mar 2, 2026

SSKN

STRATA Skin Sciences, Inc.
BEARISH
Impact 7/10
Horizonimmediate Processed7mo ago SEC0001213900-26-022339
Deregistration
Actionable Insight ▼ Bearish

Traders should anticipate reduced liquidity and limited public information for SSKN going forward. Monitor OTC trading volume and any future press releases for material updates.

DirectionBearish
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
SSKN ▼ -46.15% at T+60d
SHORT call ✓ call won +46.15% · α vs SPY +56.47% · entry $0.2600 → $0.1400
Entry = T+0 close
Mar 2, 2026
via day close
T+1d
-11.54%
call +11.54% · α +12.30%
$0.2300
settled 8mo ago
T+5d
+7.69%
call -7.69% · α -8.17%
$0.2800
settled 8mo ago
T+20d
+11.54%
call -11.54% · α -15.94%
$0.2900
settled 7mo ago
T+60d
-46.15%
call +46.15% · α +56.47%
$0.1400
settled 5mo ago

Price Chart

Loading chart...

Executive Summary

STRATA Skin Sciences, Inc. (SSKN) has filed Form 15-12G to terminate the registration of its Common Stock under Section 12(g) of the Securities Exchange Act of 1934, effectively deregistering the stock and ceasing its public reporting obligations. The company cites Rule 12g-4(a)(1), indicating it has fewer than 300 holders of record — the reported number is 157 — which allows it to deregister voluntarily. This 'going dark' move reduces transparency and liquidity for shareholders.

Key Facts

  • STRATA Skin Sciences, Inc. (SSKN) filed Form 15-12G to terminate registration of its Common Stock under Section 12(g) of the Exchange Act.
  • The filing was submitted on March 2, 2026, and is effective immediately.
  • Approximate number of holders of record: 157, qualifying the company for deregistration under Rule 12g-4(a)(1).
  • The company is no longer required to file periodic reports (e.g., 10-K, 10-Q) with the SEC.
  • SSKN is currently traded on the OTC market, where it will likely remain, but with reduced disclosure and oversight.
  • No acquisition or merger is indicated as the reason for deregistration — this appears to be a cost-saving or strategic decision due to low shareholder count.

Financial Impact

Non-quantifiable direct financial impact, but significant reduction in regulatory and reporting costs for the company. Shareholders lose access to audited financials and real-time disclosures.

transparencyliquidityinvestor accessreporting costs

Risk Factors

  • Decreased transparency increases information asymmetry, favoring insiders over public shareholders.
  • Potential decline in trading volume and liquidity on the OTC market post-deregistration.
  • Difficulty in valuation due to lack of future SEC filings like 10-Ks and 10-Qs.

Market Snapshot

Exchange
OTC

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
15-12G Filing (Primary)0001213900-26-022339
Document: 0001213900-26-022339-index-headers.html0001213900-26-022339
Document: 0001213900-26-022339-index.html0001213900-26-022339
Document: 0001213900-26-022339.txt0001213900-26-022339
2 reports for SSKN
Performance horizon
Filters
Rows
Reports for SSKN — sortable, filterable
TypeNow
Aug 19, 2026
10w ago
Court Ruling
MIXED ★ 6/10
$0.000200awaiting T+60—$0.000200 (−0.00%)
Mar 2, 2026
34w ago
15-12G
BEARISH ★ 7/10
$0.2600 $0.1400▲ +46.15%▲ +56.47%$0.000200 (+99.92%)
Showing 2 of 2

US Market Status

Market Closed — Opens in 9h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 2, 2026